Download presentation
Presentation is loading. Please wait.
Published byDwain Bell Modified over 6 years ago
1
Figure 2 Response after initial increase in total tumour burden
in a 77-year-old male with advanced-stage melanoma treated with ipilimumab Figure 2 | Response after initial increase in total tumour burden in a 77-year-old male with advanced-stage melanoma treated with ipilimumab. a | The baseline CT scan demonstrated a lung lesion (arrow) measuring 19 mm in the longest diameter. b | After 12 weeks of therapy, the lesion (arrow) measured 29 mm (53% increase compared with the baseline), indicating progressive disease by RECIST. c | The patient remained on therapy, and another follow-up CT scan (24 weeks after therapy initiation) showed a reduction in the size of the lesion (arrow), to 12 mm, indicative of an immune-related response to therapy. Reprinted from Nishino, M., Tirumani, S.H., Ramaiya, N.H. & Hodi, F.S. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment, Eur. J. Radiol., 84, 1259–1268, Copyright (2015), with permission from Elsevier. Nishino, M. et al. (2017) Monitoring immune-checkpoint blockade: response evaluation and biomarker development Nat. Rev. Clin. Oncol. doi: /nrclinonc
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.